Cost-Effectiveness of Recombinant Zoster Vaccine for Adults Aged ≥50 Years in China

疱疹后神经痛 医学 成本效益 质量调整寿命年 接种疫苗 疫苗效力 儿科 病毒学 麻醉 风险分析(工程) 神经病理性疼痛
作者
Minghuan Jiang,Xuelin Yao,Jin Peng,Liuxin Feng,Yue Ma,Xinke Shi,Yu Fang,Hai Fang
出处
期刊:American Journal of Preventive Medicine [Elsevier BV]
卷期号:65 (5): 818-826 被引量:9
标识
DOI:10.1016/j.amepre.2023.05.007
摘要

Adjuvanted recombinant zoster vaccine (RZV) was the first vaccine made available for herpes zoster in China. Authors aimed to evaluate its economic and health impacts on Chinese adults aged ≥50 years.A lifetime Markov model was developed to compare the cost-effectiveness of RZV with that of no vaccination from a societal perspective. Model inputs were derived from published literature and analyzed in 2022. Outcomes included total costs, quality-adjusted life-years, incremental cost-effectiveness ratio, and number of herpes zoster and herpes zoster-related cases. Sensitivity analyses were performed to examine the robustness of the model results.RZV was more costly than no vaccination by $2.78 billion with an additional 65,008 quality-adjusted life-years gained and could avoid 1,893,530 herpes zoster cases, 295,761 postherpetic neuralgia cases, 51,734 other complications, and 229 herpes zoster-related deaths. Incremental cost-effectiveness ratios of RZV varied in a range of $34,465.5-$51,002.7 per quality-adjusted life-year. RZV for the entire cohort would be cost-effective when discount rate was <2.4%, a waning rate of 2-dose RZV efficacy decreased to <0.8%, the utility of postherpetic neuralgia was <0.496, duration of postherpetic neuralgia was >12.86 months, or the cost of RZV per dose decreased to <$229.6. In a probabilistic sensitivity analysis, the probability of RZV being cost-effective was 43.95%, 59.32%, 45.27%, and 39.50% for people aged 50-59, 60-69, 70-79, and ≥80 years, respectively, with threefold gross domestic product per capita (37,654.5 per quality-adjusted life-year) as the willingness-to-pay threshold.RZV was most likely to be cost-effective in people aged 60-69 years. A slight decrease in vaccine cost would result in RZV being cost-effective in all people aged ≥50 years.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
肆壹完成签到,获得积分10
刚刚
刚刚
123关闭了123的文献求助
1秒前
1秒前
2秒前
李飞龙发布了新的文献求助10
2秒前
fantasy的应助被Yutong采纳,获得10
2秒前
我憋不住了完成签到,获得积分10
2秒前
CaiJJ发布了新的文献求助10
2秒前
明理诗槐完成签到,获得积分10
3秒前
yanny完成签到,获得积分10
3秒前
李健的小迷弟的应助被MK采纳,获得10
3秒前
negolos发布了新的文献求助10
4秒前
CITY111119发布了新的文献求助10
4秒前
弗洛伊德完成签到,获得积分10
6秒前
合适的寻菡完成签到,获得积分10
7秒前
7秒前
嗒帅发布了新的文献求助10
8秒前
周周发布了新的文献求助10
9秒前
9秒前
tiankong完成签到,获得积分10
9秒前
常大有完成签到,获得积分10
10秒前
小钥匙完成签到 ,获得积分10
10秒前
rylinn完成签到,获得积分10
10秒前
爆米花的应助被风中的宛白采纳,获得10
11秒前
Owen的应助被风中的宛白采纳,获得20
11秒前
田様的应助被风中的宛白采纳,获得20
11秒前
11秒前
斯文败类的应助被风中的宛白采纳,获得10
11秒前
CipherSage的应助被风中的宛白采纳,获得20
11秒前
12秒前
传奇3的应助被风中的宛白采纳,获得20
12秒前
12秒前
zyy发布了新的文献求助30
14秒前
温文儒雅鳗鱼冻完成签到,获得积分10
15秒前
流苏完成签到,获得积分20
15秒前
17秒前
共享精神的应助被Erpan采纳,获得10
17秒前
17秒前
彭于晏的应助被Lynn采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181940
求助须知:如何正确求助?哪些是违规求助? 9571697
关于积分的说明 21819181
捐赠科研通 7778330
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557767
邀请新用户注册赠送积分活动 2479621